A study showed that in NSCLC patients with EGFR mutations, pre-radiotherapy showed better results, with a median OS of 30 months for patients who received pre-WBRT and 25 months for those who received pre-EGFR-TKIs (23). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.